Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
1(50.0%)
Phase 2
1(50.0%)
2Total
N/A(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03540420Phase 2Active Not Recruiting

Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer

Role: collaborator

NCT04537741Not ApplicableActive Not Recruiting

Coronary CT Angiography in Non ST-elevation Myocardial Infarction

Role: collaborator

NCT06855121Recruiting

The Norwegian Immunotherapy in Multiple Myeloma Study

Role: collaborator

NCT01179165Completed

Noninvasive Methods in Diagnosing Coronary Heart Disease in Diabetic Patients

Role: collaborator

All 4 trials loaded